Loading clinical trials...
Loading clinical trials...
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Study of Baricitinib in Patients With Systemic Lupus Erythematosus
Conditions
Interventions
Baricitinib
Placebo
Locations
159
United States
University of Arizona Arthritis Center
Gilbert, Arizona, United States
Arizona Arthritis & Rheumatology Research
Phoenix, Arizona, United States
Arizona Arthritis & Rheumatology Associates, P. C.
Tucson, Arizona, United States
Wallace Rheumatic Studies Center
Beverly Hills, California, United States
Medvin Clinical Research - Weidmann
Covina, California, United States
Office: Dr Robin K Dore
Tustin, California, United States
Start Date
August 2, 2018
Primary Completion Date
September 24, 2021
Completion Date
October 20, 2021
Last Updated
November 23, 2022
NCT07526350
NCT06875960
NCT06335979
NCT06647069
NCT07371468
NCT06133972
Lead Sponsor
Eli Lilly and Company
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions